# Enphase Energy

Type: Company (ENPH)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/enphase-energy
Canonical HTML page: https://getbiobrief.com/entity/enphase-energy

## Timeline

- **2026-03-21**: Litigation Filed — Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
- **2022-04-18**: Partnership Termination — BMS and Nektar officially end their global clinical development collaboration.
- **2022-03-14**: Phase 3 Failure — Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
- **2018-02-14**: BMS Partnership — Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.

## Recent coverage (1 stories)

### Pomerantz LLP Files Class Action Against Nektar Therapeutics Over Disclosures
2026-03-22 02:52:13 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
Full story: https://getbiobrief.com/story/nektar-therapeutics-class-action-litigation-pomerantz

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.